UCB - Gross Profit On Sales

Stock Price
268.80
Daily Change
5.40 2.05%
Monthly
4.84%
Yearly
107.81%
Q2 Forecast
257.81

UCB reported EUR3.19B in Gross Profit on Sales for its fiscal semester ending in December of 2025.





Gross Profit On Sales Change Date
Alcon AG USD 1.52B 58M Dec/2025
Almirall EUR 429.87M 180.02M Dec/2025
Amarin USD 23.17M 961K Dec/2025
argenx SE USD 1.14B 118.49M Dec/2025
AstraZeneca USD 12.39B 5M Dec/2025
Bayer EUR 5.35B 1.02B Sep/2025
Galapagos EUR -13.57M 74.82M Sep/2025
Genmab DKK 977M 13M Dec/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
GRIFOLS EUR 743.8M 49.13M Jun/2025
Hikma Pharmaceutical USD 362.5M 329.5M Jun/2025
Lonza CHF 1.29B 248M Jun/2025
Merck EUR 2.96B 252M Dec/2025
Novartis USD 10.25B 570M Dec/2025
Orion EUR 508.7M 254.5M Dec/2025
Recordati EUR 432.41M 8.56M Sep/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
UCB EUR 3.19B 621M Dec/2025
Unibail Rodamco EUR 997M 516.9M Dec/2024